AU2016370653A1 - Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome - Google Patents
Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome Download PDFInfo
- Publication number
- AU2016370653A1 AU2016370653A1 AU2016370653A AU2016370653A AU2016370653A1 AU 2016370653 A1 AU2016370653 A1 AU 2016370653A1 AU 2016370653 A AU2016370653 A AU 2016370653A AU 2016370653 A AU2016370653 A AU 2016370653A AU 2016370653 A1 AU2016370653 A1 AU 2016370653A1
- Authority
- AU
- Australia
- Prior art keywords
- mrna
- nucleobases
- retained intron
- splice site
- ric pre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000007547 Dravet syndrome Diseases 0.000 title claims abstract description 39
- 208000036572 Myoclonic epilepsy Diseases 0.000 title claims abstract description 39
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 title claims abstract description 39
- 230000000692 anti-sense effect Effects 0.000 title claims description 123
- 208000032089 autosomal dominant 5 intellectual disability Diseases 0.000 title claims description 6
- 201000000181 autosomal dominant non-syndromic intellectual disability 5 Diseases 0.000 title claims description 6
- 238000011282 treatment Methods 0.000 title claims description 6
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 claims abstract description 291
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 claims abstract description 291
- 238000000034 method Methods 0.000 claims abstract description 180
- 239000000203 mixture Substances 0.000 claims abstract description 96
- 230000014509 gene expression Effects 0.000 claims abstract description 52
- 230000002950 deficient Effects 0.000 claims abstract description 44
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 claims abstract description 43
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 claims abstract description 42
- 208000036626 Mental retardation Diseases 0.000 claims abstract description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2679
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2592
- 108020004999 messenger RNA Proteins 0.000 claims description 469
- 230000000717 retained effect Effects 0.000 claims description 411
- 108090000623 proteins and genes Proteins 0.000 claims description 354
- 102000004169 proteins and genes Human genes 0.000 claims description 305
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 226
- 230000035772 mutation Effects 0.000 claims description 83
- 108700028369 Alleles Proteins 0.000 claims description 63
- 125000003729 nucleotide group Chemical group 0.000 claims description 52
- 239000002773 nucleotide Substances 0.000 claims description 49
- 230000001965 increasing effect Effects 0.000 claims description 44
- 108091092195 Intron Proteins 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 230000000295 complement effect Effects 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 108091027974 Mature messenger RNA Proteins 0.000 claims description 24
- 238000011144 upstream manufacturing Methods 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 17
- 230000001594 aberrant effect Effects 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 235000000346 sugar Nutrition 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 230000008859 change Effects 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 11
- 230000036961 partial effect Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 8
- 238000000185 intracerebroventricular administration Methods 0.000 claims description 8
- 238000010255 intramuscular injection Methods 0.000 claims description 8
- 239000007927 intramuscular injection Substances 0.000 claims description 8
- 239000007928 intraperitoneal injection Substances 0.000 claims description 8
- 238000007913 intrathecal administration Methods 0.000 claims description 8
- 238000010253 intravenous injection Methods 0.000 claims description 8
- 238000010254 subcutaneous injection Methods 0.000 claims description 8
- 239000007929 subcutaneous injection Substances 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 6
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 6
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 210000001161 mammalian embryo Anatomy 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 143
- 210000004027 cell Anatomy 0.000 description 78
- 108010029485 Protein Isoforms Proteins 0.000 description 17
- 102000001708 Protein Isoforms Human genes 0.000 description 17
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 17
- 230000006870 function Effects 0.000 description 15
- 230000014759 maintenance of location Effects 0.000 description 15
- 101150037222 SYNGAP1 gene Proteins 0.000 description 12
- 230000001086 cytosolic effect Effects 0.000 description 11
- 210000000805 cytoplasm Anatomy 0.000 description 10
- 210000004940 nucleus Anatomy 0.000 description 10
- 101100247331 Homo sapiens RASA2 gene Proteins 0.000 description 9
- 102100031427 Ras GTPase-activating protein 2 Human genes 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 230000014616 translation Effects 0.000 description 8
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 101000672453 Homo sapiens 60S ribosomal protein L32 Proteins 0.000 description 7
- 238000003559 RNA-seq method Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 208000031976 Channelopathies Diseases 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 4
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 4
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 102000018674 Sodium Channels Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003416 augmentation Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000008186 generalized epilepsy with febrile seizures plus Diseases 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108010027920 GTPase-Activating Proteins Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108700005079 Recessive Genes Proteins 0.000 description 2
- 102000052708 Recessive Genes Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003618 cortical neuron Anatomy 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000012259 partial gene deletion Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220002461 rs397515320 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- OAWXYINGQXLWOE-UHFFFAOYSA-N (2-acetyloxybenzoyl) 2-acetyloxybenzoate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1OC(C)=O OAWXYINGQXLWOE-UHFFFAOYSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000002110 C2 domains Human genes 0.000 description 1
- 108050009459 C2 domains Proteins 0.000 description 1
- 108700003861 Dominant Genes Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- 102000017703 GABRG2 Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 description 1
- 101000684813 Homo sapiens Sodium channel subunit beta-1 Proteins 0.000 description 1
- 208000007599 Hyperkalemic periodic paralysis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000012905 Myotonic disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 102220525612 Sodium channel protein type 1 subunit alpha_M934I_mutation Human genes 0.000 description 1
- 102220478891 Sodium channel protein type 1 subunit alpha_R1648C_mutation Human genes 0.000 description 1
- 102220478910 Sodium channel protein type 1 subunit alpha_R1648H_mutation Human genes 0.000 description 1
- 102220478795 Sodium channel protein type 1 subunit alpha_W1434R_mutation Human genes 0.000 description 1
- 102100023732 Sodium channel subunit beta-1 Human genes 0.000 description 1
- 241000656145 Thyrsites atun Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 208000027838 paramyotonia congenita of Von Eulenburg Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 208000000415 potassium-aggravated myotonia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 102220052625 rs141845119 Human genes 0.000 description 1
- 102220292666 rs143599540 Human genes 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023202216A AU2023202216A1 (en) | 2015-12-14 | 2023-04-11 | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267251P | 2015-12-14 | 2015-12-14 | |
| US62/267,251 | 2015-12-14 | ||
| PCT/US2016/066708 WO2017106377A1 (en) | 2015-12-14 | 2016-12-14 | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023202216A Division AU2023202216A1 (en) | 2015-12-14 | 2023-04-11 | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016370653A1 true AU2016370653A1 (en) | 2018-06-21 |
Family
ID=59057535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016370653A Abandoned AU2016370653A1 (en) | 2015-12-14 | 2016-12-14 | Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome |
| AU2023202216A Abandoned AU2023202216A1 (en) | 2015-12-14 | 2023-04-11 | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023202216A Abandoned AU2023202216A1 (en) | 2015-12-14 | 2023-04-11 | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11083745B2 (https=) |
| EP (2) | EP3390636B1 (https=) |
| JP (2) | JP7049248B2 (https=) |
| KR (1) | KR102604132B1 (https=) |
| CN (2) | CN116059236A (https=) |
| AU (2) | AU2016370653A1 (https=) |
| CA (1) | CA3005256A1 (https=) |
| ES (1) | ES2882500T3 (https=) |
| IL (1) | IL259222A (https=) |
| SG (1) | SG11201804443UA (https=) |
| WO (1) | WO2017106377A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| WO2017106377A1 (en) * | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| HUE070436T2 (hu) * | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| EP3717505A4 (en) * | 2017-12-01 | 2021-12-01 | Encoded Therapeutics, Inc. | GENENICALLY MODIFIED DNA-BINDING PROTEINS |
| CA3099280A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| BR112021003224A2 (pt) * | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| WO2020069199A1 (en) * | 2018-09-26 | 2020-04-02 | Case Western Reserve University | Methods and compositions for increasing protein expression and/or treating a haploinsufficiency disorder |
| WO2020115106A1 (en) * | 2018-12-04 | 2020-06-11 | Stichting Katholieke Universiteit | Antisense oligonucleotides rescue aberrant splicing of abca4 |
| US20220090087A1 (en) * | 2019-01-23 | 2022-03-24 | The Florey Institute Of Neuroscience And Mental Health | Antisense oligonucleotides targeting scn2a retained introns |
| AU2020227825B2 (en) * | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
| MX2021013081A (es) * | 2019-04-26 | 2021-12-10 | Stoke Therapeutics Inc | Métodos y composiciones para modular el corte y empalme de intrones alternativos. |
| PL3976798T3 (pl) | 2019-05-29 | 2026-04-07 | Encoded Therapeutics, Inc. | Kompozycje i sposoby selektywnej regulacji genów |
| EP4017979A4 (en) * | 2019-08-19 | 2024-03-27 | Stoke Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING PROTEIN SPLICING AND EXPRESSION |
| US11618900B2 (en) | 2019-11-01 | 2023-04-04 | The Johns Hopkins University | Modulating SYNGAP |
| EP4069255B1 (en) * | 2019-12-04 | 2025-10-01 | University of Massachusetts | Identifying non-productive splice sites |
| BR112022010882A2 (pt) * | 2019-12-06 | 2022-10-04 | Stoke Therapeutics Inc | Oligômeros antissenso para tratamento de condições e doenças |
| EP4110918A4 (en) * | 2020-02-28 | 2024-04-03 | The University of Chicago | METHODS AND COMPOSITIONS COMPRISING TRANS-ACTING TRANSLATION ACTIVATORS |
| CN115916977A (zh) * | 2020-05-11 | 2023-04-04 | 弗洛里神经科学与心理健康研究所 | 用于治疗与syngap1中功能失去突变相关的障碍的组合物和方法 |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| CN114480651B (zh) * | 2022-02-14 | 2023-10-20 | 天津市泌尿外科研究所 | Pcat1的反义寡核苷酸及其在制备抑制前列腺癌核酸药物中的应用 |
| WO2023163801A1 (en) * | 2022-02-24 | 2023-08-31 | Q-State Biosciences, Inc. | Therapeutics for syngap haploinsufficiency |
| EP4627084A1 (en) * | 2022-12-01 | 2025-10-08 | Camp4 Therapeutics Corporation | Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas |
| WO2024145496A2 (en) * | 2022-12-28 | 2024-07-04 | The University Of Chicago | Splice-switching oligonucleotides for treating syngap1-associated disorders |
| CN116334086A (zh) * | 2023-03-29 | 2023-06-27 | 广州医科大学附属第二医院 | 一种用于修复或抑制SCN1A基因异常剪接的U1-snRNA及其用途 |
| MX2025013084A (es) * | 2023-05-03 | 2026-02-03 | Stoke Therapeutics Inc | Compuestos y métodos para tratar sujetos humanos |
| WO2025090633A1 (en) * | 2023-10-23 | 2025-05-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods comprising small nuclear rna (snrna) for treating genetic epilepsies |
| WO2025199503A1 (en) * | 2024-03-22 | 2025-09-25 | Stoke Therapeutics, Inc. | Methods for treating conditions and diseases |
| WO2026065401A1 (zh) * | 2024-09-30 | 2026-04-02 | 时夕(广州)生物科技有限公司 | 一种用于调控SCN1A基因mRNA和蛋白表达的方法和化合物 |
Family Cites Families (272)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866042A (en) | 1987-11-18 | 1989-09-12 | Neuwelt Edward A | Method for the delivery of genetic material across the blood brain barrier |
| US6294520B1 (en) | 1989-03-27 | 2001-09-25 | Albert T. Naito | Material for passage through the blood-brain barrier |
| WO1992003568A1 (en) | 1990-08-13 | 1992-03-05 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5914396A (en) | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| ATE299509T1 (de) | 1992-07-23 | 2005-07-15 | Isis Pharmaceuticals Inc | Neue 2'-o-alkyl-nukleoside und -phosphoramidite, verfahren zu ihrer herstellung und ihre verwendungen |
| ATE404683T1 (de) | 1992-09-25 | 2008-08-15 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
| DE69435005T2 (de) | 1993-05-11 | 2008-04-17 | The University Of North Carolina At Chapel Hill | Antisense Oligonukleotide die anomales Splicing verhindern und deren Verwendung |
| AU1322795A (en) | 1993-12-24 | 1995-07-17 | Erasmus University Rotterdam | Tuberous sclerosis 2 gene and uses thereof |
| US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| FR2727867B1 (fr) | 1994-12-13 | 1997-01-31 | Rhone Poulenc Rorer Sa | Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| NZ331217A (en) | 1996-02-14 | 2000-02-28 | Novartis Ag | Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand |
| GB9605808D0 (en) | 1996-03-20 | 1996-05-22 | Isis Innovation | CFTR gene regulator |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| USRE44779E1 (en) | 1997-03-07 | 2014-02-25 | Santaris Pharma A/S | Bicyclonucleoside and oligonucleotide analogues |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US7011973B1 (en) | 1997-06-03 | 2006-03-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells in vivo and uses thereof |
| US6963589B1 (en) | 1997-07-03 | 2005-11-08 | Canon Kabushiki Kaisha | Information processing apparatus for and method of transmitting and/or receiving broadcast signal |
| GB9716231D0 (en) | 1997-07-31 | 1997-10-08 | Amersham Int Ltd | Base analogues |
| US7572582B2 (en) | 1997-09-12 | 2009-08-11 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| JP4236812B2 (ja) | 1997-09-12 | 2009-03-11 | エクシコン エ／エス | オリゴヌクレオチド類似体 |
| US7045610B2 (en) | 1998-04-03 | 2006-05-16 | Epoch Biosciences, Inc. | Modified oligonucleotides for mismatch discrimination |
| US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US7071324B2 (en) | 1998-10-13 | 2006-07-04 | Brown University Research Foundation | Systems and methods for sequencing by hybridization |
| US20030224514A1 (en) | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PPAR-delta expression |
| US6436657B1 (en) | 1998-12-18 | 2002-08-20 | E. I. Du Pont De Nemours And Company | Polynucleotides encoding aminomethyltransferases |
| ES2234563T5 (es) | 1999-02-12 | 2018-01-17 | Daiichi Sankyo Company, Limited | Nuevos análogos de nucleósidos y oligonucleótidos |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| KR20020013513A (ko) | 1999-03-18 | 2002-02-20 | 추후제출 | Ｘｙｌｏ-ｌｎａ 유사체 |
| DE60029314T2 (de) | 1999-03-24 | 2007-07-12 | Exiqon A/S | Verbesserte Synthese für -2.2.1. I Bicyclo-Nukleoside |
| US6734291B2 (en) | 1999-03-24 | 2004-05-11 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
| US6383752B1 (en) | 1999-03-31 | 2002-05-07 | Hybridon, Inc. | Pseudo-cyclic oligonucleobases |
| US7053207B2 (en) | 1999-05-04 | 2006-05-30 | Exiqon A/S | L-ribo-LNA analogues |
| US6083482A (en) | 1999-05-11 | 2000-07-04 | Icn Pharmaceuticals, Inc. | Conformationally locked nucleosides and oligonucleotides |
| US6531591B1 (en) | 1999-07-07 | 2003-03-11 | Exiqon A/S | Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| US6677445B1 (en) | 1999-08-27 | 2004-01-13 | Chiron Corporation | Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| US6187586B1 (en) | 1999-12-29 | 2001-02-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of AKT-3 expression |
| US6784291B2 (en) | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| US6809194B1 (en) | 2000-05-10 | 2004-10-26 | Chiron Corporation | Akt3 inhibitors |
| CA2395781C (en) | 2000-07-13 | 2010-04-13 | The Johns Hopkins University School Of Medicine | Detection and treatment of polycystic kidney disease |
| US7053199B2 (en) | 2000-08-29 | 2006-05-30 | Takeshi Imanishi | Nucleoside analogs and oligonucleotide derivatives containing these analogs |
| AU2001295531A1 (en) | 2000-09-02 | 2002-03-13 | Grünenthal GmbH | Antisense oligonucleotides against vanilloid receptor 1 |
| JP4413493B2 (ja) | 2000-10-04 | 2010-02-10 | サンタリス ファーマ アー／エス | プリンｌｎａ類似体の改善された合成方法 |
| JP2002345489A (ja) | 2000-11-03 | 2002-12-03 | Astrazeneca Ab | 化学物質 |
| ATE287413T1 (de) | 2001-07-12 | 2005-02-15 | Santaris Pharma As | Verfahren zur herstellung des lna phosphoramidite |
| AU2002336367A1 (en) | 2001-08-16 | 2003-03-03 | The Regents Of The University Of Michigan | Adamts13 genes and proteins and variants, and uses thereof |
| CA2459347C (en) | 2001-09-04 | 2012-10-09 | Exiqon A/S | Locked nucleic acid (lna) compositions and uses thereof |
| US6936589B2 (en) | 2001-09-28 | 2005-08-30 | Albert T. Naito | Parenteral delivery systems |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| EP1481983A4 (en) | 2002-02-13 | 2008-04-02 | Takeshi Imanishi | NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF |
| AU2003222743B2 (en) | 2002-05-08 | 2008-12-11 | Roche Innovation Center Copenhagen A/S | Synthesis of locked nucleic acid derivatives |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| AU2003247610A1 (en) | 2002-06-21 | 2004-01-06 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US20060058253A1 (en) | 2002-08-12 | 2006-03-16 | Benoit Chabot | Methods to reprogram splice site selection in pre-messenger rnas |
| AU2003259803B2 (en) | 2002-08-12 | 2007-08-02 | The Regents Of The University Of Michigan | Diagnosis and treatment of tuberous sclerosis |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004046160A2 (en) | 2002-11-18 | 2004-06-03 | Santaris Pharma A/S | Amino-lna, thio-lna and alpha-l-oxy-ln |
| US7217807B2 (en) | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| CA2518475C (en) | 2003-03-07 | 2014-12-23 | Alnylam Pharmaceuticals, Inc. | Irna agents comprising asymmetrical modifications |
| AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| ATE443765T1 (de) | 2003-03-21 | 2009-10-15 | Santaris Pharma As | Analoga kurzer interferierender rna (sirna) |
| NZ542687A (en) | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
| US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US20070009899A1 (en) | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| GB0326578D0 (en) | 2003-11-14 | 2003-12-17 | Univ Belfast | Cancer diagnosis and therapy |
| US20050221354A1 (en) | 2004-02-18 | 2005-10-06 | Wyeth | Nucleic acid arrays for monitoring expression profiles of drug target genes |
| JP5697297B2 (ja) | 2004-05-14 | 2015-04-08 | ロゼッタ ジノミクス リミテッド | マイクロｎａｓおよびその使用 |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US20080299104A1 (en) * | 2004-07-01 | 2008-12-04 | California Institute Of Technology | Methods for detecting agents involved in neuronal apoptosis and compositions thereof |
| US20070087376A1 (en) | 2004-08-30 | 2007-04-19 | Potashkin Judith A | Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases |
| US20060134670A1 (en) | 2004-11-19 | 2006-06-22 | Fabrice Piu | Enabling tools to identify ligands for hormone nuclear receptors |
| WO2006081311A2 (en) | 2005-01-26 | 2006-08-03 | Medical College Of Georgia Research Institute | Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors |
| US7718625B2 (en) | 2005-01-27 | 2010-05-18 | University Of South Florida | Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof |
| US20100150839A1 (en) | 2005-02-04 | 2010-06-17 | Massachusetts Institute Of Technology | Compositions and Methods for Modulating Cognitive Function |
| ES2732071T3 (es) | 2005-04-01 | 2019-11-20 | Univ Florida | Biomarcadores de lesiones hepáticas |
| EP1904630A4 (en) | 2005-06-16 | 2009-10-21 | Bionomics Ltd | METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE |
| ATE544866T1 (de) | 2005-06-17 | 2012-02-15 | Baxter Int | Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung |
| EP3470072A1 (en) | 2005-06-23 | 2019-04-17 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US8501703B2 (en) | 2005-08-30 | 2013-08-06 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds for modulation of splicing |
| WO2007047913A2 (en) | 2005-10-20 | 2007-04-26 | Isis Pharmaceuticals, Inc | Compositions and methods for modulation of lmna expression |
| WO2007048629A2 (en) | 2005-10-28 | 2007-05-03 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Modulation of rna silencing efficiency by argonaute proteins |
| US20080280848A1 (en) | 2005-10-28 | 2008-11-13 | Volker Patzel | Structures of Active Guide Rna Molecules and Method of Selection |
| US20100022495A1 (en) | 2005-11-01 | 2010-01-28 | President And Fellows Of Harvard College | Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis |
| US20090291437A1 (en) | 2005-11-02 | 2009-11-26 | O'brien Sean | Methods for targeting quadruplex sequences |
| US7785834B2 (en) | 2005-11-10 | 2010-08-31 | Ercole Biotech, Inc. | Soluble TNF receptors and their use in treatment of disease |
| EP1792981A1 (en) | 2005-12-02 | 2007-06-06 | Humboldt-Universität zu Berlin | Microginin producing proteins and nucleic acids encoding a microginin gene cluster as well as methods for creating microginins |
| EP1991677A2 (en) | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| AU2007211082B2 (en) | 2006-01-27 | 2012-09-27 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
| WO2007090071A2 (en) | 2006-01-27 | 2007-08-09 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
| US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
| JP2009536222A (ja) | 2006-05-05 | 2009-10-08 | アイシス ファーマシューティカルズ， インコーポレーテッド | Ｐｃｓｋ９の発現を調節するための化合物および方法 |
| US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
| AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
| EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
| US8927704B2 (en) | 2006-06-08 | 2015-01-06 | Amino Up Chemical Co., Ltd | Sense oligonucleotide capable of controlling the expression of iNOS and composition comprising the same |
| JPWO2008001778A1 (ja) | 2006-06-27 | 2009-11-26 | 武田薬品工業株式会社 | 遺伝子改変動物およびその用途 |
| WO2008094194A2 (en) | 2006-07-24 | 2008-08-07 | Athena Diagnostics, Inc. | Pkd mutations and evaluation of same |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| US20090264353A1 (en) | 2007-10-19 | 2009-10-22 | Santaris Pharma A/S | Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease |
| DK2099461T3 (da) | 2006-11-13 | 2012-07-02 | Santaris Pharma As | LNA Nukleoside Phosphoramidates |
| US8293684B2 (en) | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
| WO2008086807A2 (en) | 2007-01-19 | 2008-07-24 | Exiqon A/S | Mediated cellular delivery of lna oligonucleotides |
| EP2114981B1 (en) | 2007-01-29 | 2013-05-08 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
| AR065648A1 (es) | 2007-03-09 | 2009-06-24 | Pioneer Hi Bred Int | Identificacion de transportadores de amonio (amts) para la regulacion del metabolismo de nitrogeno en plantas |
| EP2130835B1 (en) | 2007-03-09 | 2012-05-23 | Riken | Compound having structure derived from mononucleoside or mononucleotide, nucleic acid, labeling substance, and method and kit for detection of nucleic acid |
| WO2008111908A1 (en) | 2007-03-15 | 2008-09-18 | Jyoti Chattopadhyaya | Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer |
| EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
| CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| DK2173760T4 (en) | 2007-06-08 | 2016-02-08 | Isis Pharmaceuticals Inc | Carbocyclic bicyclic nukleinsyreanaloge |
| AU2008272918B2 (en) | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| KR101654007B1 (ko) | 2007-08-15 | 2016-09-05 | 아이오니스 파마수티컬즈, 인코포레이티드 | 테트라하이드로피란 핵산 유사체 |
| ES2639852T3 (es) | 2007-10-26 | 2017-10-30 | Academisch Ziekenhuis Leiden | Medios y métodos para contrarrestar los trastornos musculares |
| WO2009064920A2 (en) | 2007-11-13 | 2009-05-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating protein expression |
| WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| US8846386B2 (en) | 2007-12-18 | 2014-09-30 | University Of Kentucky Research Foundation | sVEGFR-2 and its role in lymphangiogenesis modulation |
| JP5608863B2 (ja) | 2007-12-28 | 2014-10-15 | 公立大学法人横浜市立大学 | 新生児期〜乳児期発症の難治性てんかんの検出方法 |
| WO2009100320A2 (en) | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
| WO2009151691A2 (en) | 2008-03-13 | 2009-12-17 | Celera Corporation | Genetic polymorphisms associated wiith venous thrombosis, methods of detection and uses thereof |
| US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
| EP2274423A2 (en) | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
| WO2009149921A2 (en) | 2008-06-11 | 2009-12-17 | Bionucleon S.R.L. | Inhibition of hrp-3 using modified oligonucleotides |
| EP2151248A1 (en) | 2008-07-30 | 2010-02-10 | Johann Bauer | Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses |
| US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
| DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
| EP2364325A4 (en) | 2008-11-07 | 2012-07-25 | Ct Hospitalier Universitaire Sainte Justine | SYNGAP1 DYSFUNCTIONS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS FOR INTELLECTUAL SENTENCING |
| ES2600781T3 (es) | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
| US9006194B2 (en) | 2008-12-19 | 2015-04-14 | Drexel University | Compositions and methods for diminishing viral infection and inflammation associated with viral infection |
| US20100166784A1 (en) | 2008-12-30 | 2010-07-01 | The Washington University | Method and compositions for modulating th17 cell development |
| CA2750379A1 (en) | 2009-01-14 | 2010-07-22 | Gordon J. Lutz | Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease |
| JP5931720B2 (ja) | 2009-05-08 | 2016-06-08 | クルナ・インコーポレーテッド | Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療 |
| ES2699827T3 (es) | 2009-06-17 | 2019-02-13 | Biogen Ma Inc | Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto |
| EP2275545A1 (en) | 2009-07-16 | 2011-01-19 | Julius-Maximilians-Universität Würzburg | Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis |
| US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
| US20120252877A1 (en) | 2009-08-14 | 2012-10-04 | Theramind Research, Llc | Methods and compositions for treatment of tuberous sclerosis complex |
| CN102918163B (zh) | 2009-09-08 | 2016-10-05 | 美国控股实验室公司 | 用于诊断自闭症谱系障碍的组合物和方法 |
| WO2011032034A2 (en) | 2009-09-10 | 2011-03-17 | University Of Idaho | Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids |
| CA2778171C (en) | 2009-10-29 | 2017-07-25 | Osaka University | Bridged artificial nucleoside and nucleotide |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| US9334495B2 (en) | 2009-11-25 | 2016-05-10 | Elitechgroup B.V. | Minor groove binder (MGB)-oligonucleotide miRNA antagonists |
| WO2011085102A1 (en) | 2010-01-11 | 2011-07-14 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US8957040B2 (en) | 2010-02-08 | 2015-02-17 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
| JP2013529181A (ja) | 2010-03-25 | 2013-07-18 | ザ ジェイ． デヴィッド グラッドストーン インスティテューツ | 神経障害を治療するための組成物および方法 |
| WO2011127210A1 (en) | 2010-04-06 | 2011-10-13 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
| US20110269735A1 (en) | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| CA2796722C (en) | 2010-04-19 | 2021-06-01 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
| US9156873B2 (en) | 2010-04-28 | 2015-10-13 | Isis Pharmaceuticals, Inc. | Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom |
| US8802642B2 (en) | 2010-04-28 | 2014-08-12 | Iowa State University Research Foundation, Inc. | Spinal muscular atrophy treatment via targeting SMN2 catalytic core |
| US20130184223A1 (en) | 2010-05-20 | 2013-07-18 | University Of Rochester | Methods and compositions related to modulating autophagy |
| US8957200B2 (en) | 2010-06-07 | 2015-02-17 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| US9518259B2 (en) | 2010-06-15 | 2016-12-13 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating interaction between proteins and target nucleic acids |
| CN109112126B (zh) * | 2010-06-23 | 2024-06-14 | 库尔纳公司 | 通过抑制电压门控钠通道α亚基(SCNA)的天然反义转录物而治疗SCNA相关疾病 |
| KR101865433B1 (ko) | 2010-10-22 | 2018-07-13 | 큐알엔에이, 인크. | 알파-l 이두로니다아제 (idua)에 대한 자연 안티센스 전사체의 저해에 의한 idua 관련된 질환의 치료 |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| US20130309246A1 (en) | 2011-02-02 | 2013-11-21 | The Trustees Of Princeton University | Jagged1 as a marker and therapeutic target for breast cancer bone metastasis |
| WO2012138487A2 (en) | 2011-04-07 | 2012-10-11 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| EP3495497B1 (en) | 2011-04-28 | 2021-03-24 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
| WO2012168435A1 (en) | 2011-06-10 | 2012-12-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of leber congenital amaurosis |
| US20140357558A1 (en) | 2011-06-24 | 2014-12-04 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of spinal muscular atrophy |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US8592156B2 (en) | 2011-08-08 | 2013-11-26 | Roche Molecular Systems, Inc. | Predicting response to anti-CD20 therapy in DLBCL patients |
| WO2013033230A1 (en) | 2011-08-29 | 2013-03-07 | Isis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2753694B1 (en) | 2011-09-05 | 2017-08-23 | Stichting Katholieke Universiteit | Antisense oligonucleotides for the treatment of leber congenital amaurosis |
| MX365525B (es) | 2011-09-06 | 2019-06-06 | Curna Inc | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. |
| WO2013043878A2 (en) | 2011-09-20 | 2013-03-28 | The George Washington University | Alternative splicing variants of genes associated with prostate cancer risk and survival |
| WO2013068441A1 (en) | 2011-11-11 | 2013-05-16 | Santaris Pharma A/S | Compounds for the modulation of smn2 splicing |
| WO2013074814A2 (en) | 2011-11-15 | 2013-05-23 | University Of Utah Research Fourdation | Morpholinos, morpholino upregulating, and associated methods |
| EP2966180B1 (en) | 2011-11-29 | 2017-08-16 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
| EP2802674B1 (en) | 2012-01-11 | 2020-12-16 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of ikbkap splicing |
| WO2013120003A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
| DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| US8846885B2 (en) | 2012-02-17 | 2014-09-30 | Ajinomoto Co., Inc. | Oligonucleotide with protected base |
| EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| WO2013159108A2 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| US20140378526A1 (en) | 2012-05-11 | 2014-12-25 | City Of Hope | Design of nucleic acid binding molecules with non-watson crick and non-canonical pairing based on artificial mutation consensus sequences to counter escape mutations |
| WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN104781271B (zh) | 2012-08-20 | 2018-07-06 | 加利福尼亚大学董事会 | 具有生物可逆的基团的多核苷酸 |
| WO2014045283A1 (en) | 2012-09-24 | 2014-03-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Restoration of the cftr function by splicing modulation |
| WO2014049536A2 (en) | 2012-09-25 | 2014-04-03 | Universidade De Lisboa | Drug targets for cystic fibrosis and other conditions |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2014066915A2 (en) | 2012-10-26 | 2014-05-01 | Smith Larry J | Methods and compositions to produce ss-rnai activity with enhanced potency |
| US9909128B2 (en) | 2012-11-15 | 2018-03-06 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| CN103667438B (zh) | 2013-01-07 | 2015-04-01 | 赵晨 | 一种筛查HRDs致病突变的方法及涉及的基因芯片杂交探针设计方法 |
| CA2897522A1 (en) | 2013-01-18 | 2014-07-24 | Anna Mary Rose | Therapeutics and diagnostics based on minisatellite repeat element 1 (msr1) |
| WO2014121287A2 (en) | 2013-02-04 | 2014-08-07 | Isis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
| WO2014126229A1 (ja) | 2013-02-18 | 2014-08-21 | 塩野義製薬株式会社 | 含窒素複素環構造を有するヌクレオシド及びヌクレオチド |
| WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| US10590412B2 (en) | 2013-04-19 | 2020-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation nucleic acids through nonsense mediated decay |
| DK2992098T3 (da) | 2013-05-01 | 2019-06-17 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| WO2014198890A1 (en) | 2013-06-13 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria |
| WO2014201413A1 (en) | 2013-06-14 | 2014-12-18 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating non-coding rna |
| WO2014209841A2 (en) | 2013-06-25 | 2014-12-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CA2921556A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating rna |
| WO2015023938A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Epigenetic regulators of frataxin |
| JP2016531570A (ja) | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| US20160201064A1 (en) | 2013-08-16 | 2016-07-14 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| EP3041958B1 (en) | 2013-09-04 | 2019-12-04 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
| US11236338B2 (en) | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| EP3044315B1 (en) | 2013-09-11 | 2019-02-20 | Synthena AG | Nucleic acids and methods for the treatment of pompe disease |
| AU2014352773B2 (en) | 2013-11-21 | 2021-04-29 | Memorial Sloan-Kettering Cancer Center | Specification of functional cranial placode derivatives from human pluripotent stem cells |
| US10119168B2 (en) | 2014-03-12 | 2018-11-06 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of kidney fibrosis |
| US20170044540A1 (en) | 2014-04-22 | 2017-02-16 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| KR102524543B1 (ko) | 2014-06-10 | 2023-04-20 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드 |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| GB201411468D0 (en) | 2014-06-27 | 2014-08-13 | Univ Edinburgh | Novel treatment for endometriosis |
| WO2016027168A2 (en) | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
| CA2958524A1 (en) | 2014-08-20 | 2016-02-25 | Lifesplice Pharma Llc | Splice modulating oligonucleotides and methods of use thereof |
| AU2015327836B2 (en) | 2014-10-03 | 2021-07-01 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| EP3207048A4 (en) | 2014-10-17 | 2018-05-30 | The Broad Institute, Inc. | Compositions and methods of treating muscular dystrophy |
| CA2964979A1 (en) | 2014-11-14 | 2016-05-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of proteins |
| GB201421379D0 (en) | 2014-12-02 | 2015-01-14 | Isis Innovation Ltd And Medical Res Council | Molecule |
| JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| EP3259356B1 (en) | 2015-02-20 | 2021-12-01 | Rosalind Franklin University of Medicine and Science | Antisense compounds targeting genes associated with cystic fibrosis |
| EP3262056A4 (en) | 2015-02-27 | 2018-09-19 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| MX2017012426A (es) | 2015-04-03 | 2018-01-26 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de tmprss6. |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| US20180265911A1 (en) | 2015-09-24 | 2018-09-20 | The Trustees Of The University Of Pennsylvania | Triptycene derivatives for nucleic acid junction stabilization |
| GB2591194B (en) | 2015-10-09 | 2021-10-13 | Univ Southampton | Modulation of gene expression and screening for deregulated protein expression |
| CN108603230A (zh) | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス，インコーポレーテッド | てんかんの治療方法 |
| CA3005245A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of alagille syndrome |
| JP2019500345A (ja) | 2015-12-14 | 2019-01-10 | コールド スプリング ハーバー ラボラトリー | 肝臓病の処置のための組成物および方法 |
| WO2017106377A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| JP7036723B2 (ja) | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| JP2018538287A (ja) | 2015-12-14 | 2018-12-27 | コールド スプリング ハーバー ラボラトリー | 多発性嚢胞腎の処置のためのアンチセンスオリゴマー |
| EP3390635A4 (en) | 2015-12-14 | 2019-05-01 | Cold Spring Harbor Laboratory | Antisense oligomers for the treatment of a tuberous sclerosis complex |
| EP3390666A4 (en) | 2015-12-14 | 2019-08-07 | Cold Spring Harbor Laboratory | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES |
| ES2903394T3 (es) | 2015-12-14 | 2022-04-01 | Cold Spring Harbor Laboratory | Composiciones para el tratamiento de la retinitis pigmentosa 13 |
| JP7049249B2 (ja) | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 中枢神経系疾患の処置のための組成物および方法 |
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CN109843914B (zh) | 2016-07-06 | 2024-03-15 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛相关病症的材料和方法 |
| US20190218255A1 (en) | 2016-09-16 | 2019-07-18 | Olipass Corporation | Scn9a antisense oligonucleotides |
| MX2019011772A (es) | 2017-04-03 | 2020-01-09 | Encoded Therapeutics Inc | Expresion transgenica selectiva de tejidos. |
| CA3059775A1 (en) | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| JP2020519594A (ja) | 2017-05-09 | 2020-07-02 | ゾゲニクス インターナショナル リミテッド | フェンフルラミンを用いるドゥーゼ症候群の治療方法 |
| US20200085838A1 (en) | 2017-05-16 | 2020-03-19 | Praxis Precision Medicines, Inc. | Methods of treating epilepsy and neurodevelopmental disorders |
| KR102318434B1 (ko) | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| HUE070436T2 (hu) | 2017-10-23 | 2025-06-28 | Stoke Therapeutics Inc | Antiszensz oligomerek nonszensz-mediált RNS-lebomláson alapuló állapotok és betegségek kezelésére |
| EP3717505A4 (en) | 2017-12-01 | 2021-12-01 | Encoded Therapeutics, Inc. | GENENICALLY MODIFIED DNA-BINDING PROTEINS |
| WO2019191341A1 (en) | 2018-03-27 | 2019-10-03 | Factor Bioscience Inc. | Nucleic acid-based therapeutics |
| CA3096407A1 (en) | 2018-04-09 | 2019-10-17 | Allen Institute | Rescuing voltage-gated sodium channel function in inhibitory neurons |
| EP3806834A4 (en) | 2018-05-25 | 2022-07-27 | The Florey Institute of Neuroscience and Mental Health | DYNAMIC CLAMPS AND METHODS OF USE THEREOF |
| US20210228531A1 (en) | 2018-06-05 | 2021-07-29 | Tufts Medical Center, Inc. | Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders |
| EP3810776A1 (en) | 2018-06-22 | 2021-04-28 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating scn9a expression |
| BR112021003224A2 (pt) | 2018-08-20 | 2021-07-20 | Rogcon, Inc. | oligonucleotídeos antissentido direcionados a scn2a para o tratamento de encefalopatias por scn1a |
| US10905778B2 (en) | 2018-09-26 | 2021-02-02 | Case Western Reserve University | Methods and compositions for treating a premature stop codon-mediated disorder |
| AU2020227825B2 (en) | 2019-02-27 | 2026-03-26 | Stoke Therapeutics, Inc. | Antisense oligomers for treatment of conditions and diseases |
-
2016
- 2016-12-14 WO PCT/US2016/066708 patent/WO2017106377A1/en not_active Ceased
- 2016-12-14 ES ES16876616T patent/ES2882500T3/es active Active
- 2016-12-14 CA CA3005256A patent/CA3005256A1/en active Pending
- 2016-12-14 JP JP2018529250A patent/JP7049248B2/ja not_active Expired - Fee Related
- 2016-12-14 KR KR1020187019006A patent/KR102604132B1/ko active Active
- 2016-12-14 CN CN202211146489.4A patent/CN116059236A/zh active Pending
- 2016-12-14 CN CN201680081827.7A patent/CN109312343B/zh not_active Expired - Fee Related
- 2016-12-14 SG SG11201804443UA patent/SG11201804443UA/en unknown
- 2016-12-14 EP EP16876616.0A patent/EP3390636B1/en active Active
- 2016-12-14 AU AU2016370653A patent/AU2016370653A1/en not_active Abandoned
- 2016-12-14 US US16/062,286 patent/US11083745B2/en active Active
- 2016-12-14 EP EP21167500.4A patent/EP3933041B1/en active Active
-
2018
- 2018-05-08 IL IL259222A patent/IL259222A/en unknown
-
2021
- 2021-06-23 US US17/356,147 patent/US20220088058A1/en not_active Abandoned
-
2022
- 2022-02-01 JP JP2022013860A patent/JP2022062140A/ja active Pending
-
2023
- 2023-04-11 AU AU2023202216A patent/AU2023202216A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017106377A1 (en) | 2017-06-22 |
| CA3005256A1 (en) | 2017-06-22 |
| JP2022062140A (ja) | 2022-04-19 |
| EP3390636A4 (en) | 2019-08-14 |
| CN109312343A (zh) | 2019-02-05 |
| EP3933041A1 (en) | 2022-01-05 |
| SG11201804443UA (en) | 2018-06-28 |
| KR20180093977A (ko) | 2018-08-22 |
| US20180369275A1 (en) | 2018-12-27 |
| IL259222A (en) | 2018-07-31 |
| CN116059236A (zh) | 2023-05-05 |
| EP3390636B1 (en) | 2021-05-19 |
| EP3390636A1 (en) | 2018-10-24 |
| JP7049248B2 (ja) | 2022-04-06 |
| AU2023202216A1 (en) | 2023-07-06 |
| US11083745B2 (en) | 2021-08-10 |
| JP2019501892A (ja) | 2019-01-24 |
| EP3933041B1 (en) | 2024-01-31 |
| US20220088058A1 (en) | 2022-03-24 |
| ES2882500T3 (es) | 2021-12-02 |
| KR102604132B1 (ko) | 2023-11-17 |
| CN109312343B (zh) | 2022-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102604132B1 (ko) | 상염색체 우성 정신 지체 5 및 드라베 증후군의 치료를 위한 안티센스 올리고머 | |
| KR101840618B1 (ko) | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 | |
| KR102124228B1 (ko) | 안드로겐 수용체 발현의 조절 | |
| AU2021203300B2 (en) | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection | |
| KR20220062517A (ko) | 결합 변형된 올리고머 화합물 및 이의 용도 | |
| KR20200140805A (ko) | Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도 | |
| KR102149483B1 (ko) | 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도 | |
| KR102236784B1 (ko) | 성장 호르몬 수용체의 조절인자 | |
| KR20220012230A (ko) | 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물 | |
| KR20230043914A (ko) | App 발현을 감소시키기 위한 화합물 및 방법 | |
| KR20090087486A (ko) | 타입 ２ 당뇨병의 유전적 감수성 변이 | |
| CN101631876A (zh) | 2型糖尿病的遗传易感性变体 | |
| CN116157522A (zh) | A1cf抑制剂用于治疗乙型肝炎病毒感染的用途 | |
| CN112771162B (zh) | 用剪接转换寡核苷酸靶向kit诱导肥大细胞凋亡 | |
| US20040115641A1 (en) | Modulation of ROCK 1 expression | |
| KR20230074214A (ko) | 지방간 질환의 치료 방법 | |
| KR20230005933A (ko) | Atxn1을 조정하는 화합물 및 방법 | |
| KR102642320B1 (ko) | 항암제에 대한 내성 진단용 조성물 | |
| CN111556894A (zh) | 用于调控gsk3b表达的寡核苷酸 | |
| TW202305132A (zh) | 用於抑制α-突觸核蛋白表達之反義寡核苷酸 | |
| CN117836411A (zh) | 使用α-N-乙酰半乳糖胺α-2,6-唾液酸转移酶5(ST6GALNAC5)抑制剂治疗认知障碍 | |
| EA048246B1 (ru) | Способ лечения жировой болезни печени | |
| HK40036482A (en) | Oligonucleotides for modulating gsk3b expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ AZNAREZ, ISABEL; NASH, HUW M. AND KRAINER, ADRIAN |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |